Frank Hodi, MD
Enriched profileDirector of the Melanoma Center and Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center; Professor of Medicine at Harvard Medical School; Sharon Crowley Martin Chair in Melanoma · Dana-Farber Cancer Institute
Frank Hodi is Director of the Melanoma Center and Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center; Professor of Medicine at Harvard Medical School; Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute. OpenAlex indexes 1,583 publications with 163,663 citations (h-index 155); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 23 Oct 2026
F. Stephen Hodi Jr., MD, is Director of the Melanoma Center and Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center at Dana-Farber Cancer Institute / Harvard Medical School. The public record shows 1,583 publications with 163,663 citations (h-index 155), centered on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 12 companies, 9 NIH-funded awards (1998–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 24 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 510.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Sponsor: National Cancer Institute (NCI)
- Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Sponsor: National Cancer Institute (NCI)
- Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 23 Oct 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- Genentech USA, Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20242 payments
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Tafinlar100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
9 NIH research awards on record, funded 1998–2026 per NIH RePORTER. The latest:
Congress activity
Updated 23 Oct 2026
219 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ENDO, ESMO per OpenAlex. The most recent:
- Abstract 2217: Immune-active and mesenchymal endothelial programs define TLS presence in the tumor microenvironment.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.
Clinical cancer research
Article2026 - Tobacco Use and Cessation Patterns Among Cancer Survivors: Results From Nine ECOG-ACRIN Cancer Research Group Trials.
JCO oncology practice
Article2026 - Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors.
Clinical cancer research
Clinical Trial2026 - First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Improved Survival with Ipilimumab in Patients with Metastatic MelanomaArticle15,156 citations2010
- 02Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerArticle12,604 citations2012
- 03Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaArticle8,140 citations2015
- 04Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaArticle5,349 citations2017
- 05Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsArticle5,224 citations2014
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/frank-hodi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Bachelor's degree from Harvard University
biochemical sciences
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- Founding Member
Society for Melanoma Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Member
American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sitcancer.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hms.harvard.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Jedd Wolchok, MD
Weill Cornell Medicine
Omid Hamid, MD
The Angeles Clinic and Research Institute
Mario Sznol, MD
University of Miami Miller School of Medicine
Igor Puzanov, MD
Roswell Park Comprehensive Cancer Center